A. Tessmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. Tessmer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
N. Suttorp
2 shared publicationsT. Welte
2 shared publicationsG. Barten
1 shared publicationM. Schnoor
Institute of Social Medicine, Medical University Schleswig-Holstein, Campus Luebeck , Germany
1 shared publicationP. Martus
Department of Biometry and Clinical Epidemiology , Charité-University Medicine , Berlin , Germany
1 shared publicationR. Marre
Department of Medical Microbiology and Hygiene , University of Ulm , Germany
1 shared publication
Latest Publications
- 9 December 2010
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 38 (1) , 147-153
Influenza vaccination is associated with reduced severity of community-acquired pneumonia
Pneumonia is an important cause of influenza-associated morbidity and mortality. Influenza vaccination has been shown to reduce morbidity and mortality during influenza seasons. Protection from severe pneumonia may contribute to the beneficial effect of influenza vaccination. Therefore, we investigated the impact of prior influenza vaccination on disease severity and mortality in patients with community-acquired pneumonia (CAP).Analysis from an observational, multicentre cohort study initiated by the German competence network for CAP was performed. Patients were analysed separately as an influenza season and off-season cohort. Associations between vaccination status and outcome parameters were evaluated by multivariate analyses.In the season cohort (2,368 patients) CAP in vaccinated patients was significantly less severe according to most analysed parameters (CURB index ≥1: OR 0.76, 95% CI 0.60–0.98; procalcitonin ≥2.0 ng·mL−1: OR 0.53, 95% CI 0.35–0.81; procalcitonin ≥0.5 ng·mL−1: OR 0.71, 95% CI 0.51–0.99) and these patients showed a significantly better overall survival within the 6-month follow-up period (HR 0.63, 95% CI 0.45–0.89). Within the off-season cohort (2,632 patients) there was no significant influence of vaccination status on CAP severity or disease outcome.In conclusion, prior influenza vaccination was associated with less severe clinical course and improved overall long-term survival in patients with CAP during influenza seasons.
- 9 December 2010
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 38 (1) , 147-153
Influenza vaccination is associated with reduced severity of community-acquired pneumonia
Pneumonia is an important cause of influenza-associated morbidity and mortality. Influenza vaccination has been shown to reduce morbidity and mortality during influenza seasons. Protection from severe pneumonia may contribute to the beneficial effect of influenza vaccination. Therefore, we investigated the impact of prior influenza vaccination on disease severity and mortality in patients with community-acquired pneumonia (CAP).Analysis from an observational, multicentre cohort study initiated by the German competence network for CAP was performed. Patients were analysed separately as an influenza season and off-season cohort. Associations between vaccination status and outcome parameters were evaluated by multivariate analyses.In the season cohort (2,368 patients) CAP in vaccinated patients was significantly less severe according to most analysed parameters (CURB index ≥1: OR 0.76, 95% CI 0.60–0.98; procalcitonin ≥2.0 ng·mL−1: OR 0.53, 95% CI 0.35–0.81; procalcitonin ≥0.5 ng·mL−1: OR 0.71, 95% CI 0.51–0.99) and these patients showed a significantly better overall survival within the 6-month follow-up period (HR 0.63, 95% CI 0.45–0.89). Within the off-season cohort (2,632 patients) there was no significant influence of vaccination status on CAP severity or disease outcome.In conclusion, prior influenza vaccination was associated with less severe clinical course and improved overall long-term survival in patients with CAP during influenza seasons.
- Open Access
- 5 March 2009
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (5) , 1025-1033
Impact of intravenous -lactam/macrolide versus -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia
Guidelines recommend dual-therapy consisting of a β-lactam/macrolide (BLM) for hospitalized patients with community-acquired pneumonia. Nevertheless, the superiority over β-lactam-monotherapy (BL) remains unproven. Analyses from an observational study initiated by the German competence network CAPNETZ were performed. One thousand eight hundred and fifty-four patients were treated with either BL (49.0%) or BLM (51.0%). BLM therapy was associated with lower adjusted 14 day mortality [odds ratio (OR) 0.53; 95% confidence interval (CI): 0.30–0.94]. CRB65, neoplastic disease, age and nursing home residency were confirmed as independent predictors of death. Adjusted 14 day mortality risk was clearly reduced in patients with CRB65 = 2 (n = 411; OR 0.35; CI: 0.12–0.99) and CRB65 ≥ 2 (n = 519; OR 0.42; CI: 0.18–0.997). However, this could not be shown for adjusted 30 day mortality. Patients with CRB65 ≤ 1 showed low mortality (2.1%) without the influence of BLM. BLM therapy was associated with lower adjusted risk of treatment failure at 14 days (n = 1854; OR 0.65; CI: 0.47–0.89) and 30 days (OR 0.69; CI: 0.51–0.94) as well as in the subgroup of patients with CRB65 = 2 and CRB65 ≥ 2. This study suggests the superiority of BLM therapy in patients with CRB65 risk classes of 2 or higher on 14 day mortality. BLM therapy was also associated with lower risk of treatment failure.
- 5 March 2009
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (5) , 1025-1033
Open AccessImpact of intravenous -lactam/macrolide versus -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia
Guidelines recommend dual-therapy consisting of a β-lactam/macrolide (BLM) for hospitalized patients with community-acquired pneumonia. Nevertheless, the superiority over β-lactam-monotherapy (BL) remains unproven. Analyses from an observational study initiated by the German competence network CAPNETZ were performed. One thousand eight hundred and fifty-four patients were treated with either BL (49.0%) or BLM (51.0%). BLM therapy was associated with lower adjusted 14 day mortality [odds ratio (OR) 0.53; 95% confidence interval (CI): 0.30–0.94]. CRB65, neoplastic disease, age and nursing home residency were confirmed as independent predictors of death. Adjusted 14 day mortality risk was clearly reduced in patients with CRB65 = 2 (n = 411; OR 0.35; CI: 0.12–0.99) and CRB65 ≥ 2 (n = 519; OR 0.42; CI: 0.18–0.997). However, this could not be shown for adjusted 30 day mortality. Patients with CRB65 ≤ 1 showed low mortality (2.1%) without the influence of BLM. BLM therapy was associated with lower adjusted risk of treatment failure at 14 days (n = 1854; OR 0.65; CI: 0.47–0.89) and 30 days (OR 0.69; CI: 0.51–0.94) as well as in the subgroup of patients with CRB65 = 2 and CRB65 ≥ 2. This study suggests the superiority of BLM therapy in patients with CRB65 risk classes of 2 or higher on 14 day mortality. BLM therapy was also associated with lower risk of treatment failure.